Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

American Association of Anatomist announces winners of Young Investigator Awards

The American Association of Anatomist's (AAA) Young Investigator Awards combine three long-standing AAA awards-Bensley, Herrick, and Mossman-with the Morphological Sciences Award, all recognizing investigators in the early stages of their careers who have made important contributions to biomedical science through their research in cell/molecular biology, developmental biology, comparative neuroanatomy, or the morphological sciences.

12 Dec 2012

TKI-resistant human leukemia stem cells are the source of genomic instability

An international team of scientists, led by researchers from Temple University School of Medicine, has found that a source of mounting genomic chaos, or instability, common to chronic myeloid leukemia (CML) may lie in a pool of leukemia stem cells that are immune to treatment with potent targeted anticancer drugs.

12 Dec 2012

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ASH Annual Meeting and Exposition.

12 Dec 2012

U-M devises new system to capture and study circulating tumor cells

A glass plate with a nanoscale roughness could be a simple way for scientists to capture and study the circulating tumor cells that carry cancer around the body through the bloodstream.

12 Dec 2012

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Astellas Pharma Inc. and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Studies examine current treatment standards for patients with clotting disorders

Studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) examine current treatment standards for patients with clotting disorders in an effort to improve outcomes.

11 Dec 2012

Tacrolimus plus sirolimus not better than standard regimen in preventing GVHD

An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of Hematology annual meeting.

11 Dec 2012

Research unveils key gaps in continuity of care for sickle cell patients

Research unveiling key gaps in continuity of care for sickle cell patients transitioning from pediatric to adult care will be presented this week during the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial.

11 Dec 2012

Transplanting spermatogonial stem cells could restore fertility in male cancer patients

Radiation and chemotherapy can pack a powerful punch against all kinds of cancers. Those who survive, however, are often left with bad news: Their treatments have rendered them infertile.

11 Dec 2012

Intensified chemotherapy can reduce risk of relapse in pediatric patients with B-ALL

Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston.

11 Dec 2012

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

Ligand Pharmaceuticals Incorporated announced today that it has initiated a pivotal trial of Captisol-enabled, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.

11 Dec 2012

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of new clinical data with the Company's targeted anticancer compound, IMGN901.

11 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

BioCision introduces cryopreservation products to support stem cell research programs

As part of its ongoing effort to support the scientific community, BioCision LLC, a leader in the advanced temperature management of biomedical samples, announced the availability of free "Cool Stem Kits" to academic stem cell research programs in the U.S. and Europe.

10 Dec 2012

Pfizer joins WIN Consortium to improve personalized cancer care

Worldwide Innovative Network (WIN) in personalized cancer medicine consortium today proudly announced that Pfizer, Inc (NYSE:PFE) is the first pharmaceutical company to become a member of the consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of leading academic, industry, and patient advocacy organizations working to make personalized cancer care a reality for patients worldwide.

10 Dec 2012

Apollo launches telemedicine service in Yangon

The Apollo Group of Hospitals, one of Asia's largest healthcare providerm, formally announced the launch of its telemedicine service in Yangon on 4th December 2012.

10 Dec 2012

Ibrutinib may effectively combat chronic lymphocytic leukemia

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

10 Dec 2012

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse. These leukemia stem cells are full of genetic errors, loaded with potentially lethal breaks in DNA, and are in a state of constant self-repair.

10 Dec 2012

Treadmill test can accurately predict coronary artery disease in women over 65

Although there is a widespread belief among physicians that the exercise treadmill test (ETT) is not reliable in evaluating the heart health of women, UC Davis researchers have found that the test can accurately predict coronary artery disease in women over the age of 65. They also found that two specific electrocardiogram (EKG) indicators of heart stress during an ETT further enhanced its predictive power.

8 Dec 2012

Stem Cells News and Research

Further Reading

American Association of Anatomist announces winners of Young Investigator Awards

TKI-resistant human leukemia stem cells are the source of genomic instability

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

U-M devises new system to capture and study circulating tumor cells

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Studies examine current treatment standards for patients with clotting disorders

Tacrolimus plus sirolimus not better than standard regimen in preventing GVHD

Research unveils key gaps in continuity of care for sickle cell patients

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

Transplanting spermatogonial stem cells could restore fertility in male cancer patients

Intensified chemotherapy can reduce risk of relapse in pediatric patients with B-ALL

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

BioCision introduces cryopreservation products to support stem cell research programs

Pfizer joins WIN Consortium to improve personalized cancer care

Apollo launches telemedicine service in Yangon

Ibrutinib may effectively combat chronic lymphocytic leukemia

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Treadmill test can accurately predict coronary artery disease in women over 65

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo